Contineum Therapeutics Inc [NASDAQ: CTNM] price surged by 3.98 percent to reach at $0.4.
A sum of 155702 shares traded at recent session while its average daily volume was at 254.43K shares. Contineum Therapeutics Inc shares reached a high of $10.545 and dropped to a low of $9.85 until finishing in the latest session at $10.45.
The one-year CTNM stock forecast points to a potential upside of 54.33. The average equity rating for CTNM stock is currently 1.17, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Contineum Therapeutics Inc [CTNM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTNM shares is $22.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTNM stock is a recommendation set at 1.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Contineum Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 20, 2025. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on October 22, 2024, representing the official price target for Contineum Therapeutics Inc stock. Previously, the target price had yet another raise to $29, while Stifel analysts kept a Buy rating on CTNM stock.
The Price to Book ratio for the last quarter was 1.58, with the Price to Cash per share for the same quarter was set at 6.26.
CTNM Stock Performance Analysis:
Contineum Therapeutics Inc [CTNM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.13. With this latest performance, CTNM shares gained by 77.12% in over the last four-week period, additionally plugging by 48.44% over the last 6 months – not to mention a drop of -28.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTNM stock in for the last two-week period is set at 76.02, with the RSI for the last a single of trading hit 0.91, and the three-weeks RSI is set at 0.76 for Contineum Therapeutics Inc [CTNM]. The present Moving Average for the last 50 days of trading for this stock 6.01, while it was recorded at 10.14 for the last single week of trading, and 8.04 for the last 200 days.
Contineum Therapeutics Inc (CTNM) Capital Structure & Debt Analysis
According to recent financial data for Contineum Therapeutics Inc. ( CTNM), the Return on Equity (ROE) stands at -29.24%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -28.13%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Contineum Therapeutics Inc’s Return on Invested Capital (ROIC) is -32.37%, showcasing its effectiveness in deploying capital for earnings.
Contineum Therapeutics Inc (CTNM) Efficiency & Liquidity Metrics
Based on Contineum Therapeutics Inc’s (CTNM) latest financial statements, the Debt-to-Equity Ratio is 0.03%, indicating its reliance on debt financing relative to shareholder equity.
Contineum Therapeutics Inc (CTNM) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Contineum Therapeutics Inc. (CTNM) effectively leverages its workforce, generating an average of -$1386829.27 per employee. The company’s liquidity position is robust, with a Current Ratio of 24.51% and a Quick Ratio of 24.51%, indicating strong ability to cover short-term liabilities.
CTNM Stock EPS
With the latest financial reports released by the company, Contineum Therapeutics Inc posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.43/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CTNM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Contineum Therapeutics Inc go to -7.66%.
Contineum Therapeutics Inc [CTNM] Institutonal Ownership Details
There are presently around $73.94%, or 75.15%% of CTNM stock, in the hands of institutional investors. The top three institutional holders of CTNM stocks are: SUVRETTA CAPITAL MANAGEMENT, LLC with ownership of 2.05 million shares, which is approximately 7.9824%. JOHNSON & JOHNSON, holding 1.98 million shares of the stock with an approximate value of $$34.85 million in CTNM stocks shares; and JOHNSON & JOHNSON, currently with $$27.59 million in CTNM stock with ownership which is approximately 6.0905%.
